SlideShare ist ein Scribd-Unternehmen logo
1 von 33
Downloaden Sie, um offline zu lesen
Patient Care in Pharmacy
Practice
Anas Bahnassi PhD
Anas Bahnassi PhD CDM CDE 2
Patient-Centered Care
Care centered on patients’ needs
and expectations
3Anas Bahnassi PhD CDM CDE
Goals of
Pharmaceutical Care
Cure of a disease
Elimination or reduction of a patient’s
symptoms
Arresting or slowing of a disease process
Preventing a disease or symptomatology
4Anas Bahnassi PhD CDM CDE
The central component of
Pharmaceutical Care is:
CARING ABOUT THE PATIENT.
5Anas Bahnassi PhD CDM CDE
Pharmaceutical Care
Process
Initiate
relationship with
the patient or
caregiver
Gather patient
information
(subjective and
objective)
Assess info
(patient
assessment)
Develop
pharmaceutical
care plan
Complete
InterventionImplement
follow-up
6Anas Bahnassi PhD CDM CDE
Primary Elements of
Pharmaceutical Care
The need of the society
to address Drug
Related Problems
(DRPs) A patient-centered
approach to
meet this need
A practice based on
“caring”
about and for patients
Responsibility for
finding and
responding to the
patient’s DRPs
7Anas Bahnassi PhD CDM CDE
Pharmacist responsibility in
Pharmaceutical Care
To ensure that the patient’s drug therapy is appropriately
indicated, the most effective available, the safest possible, the
most convenient to take, and the most economical
To identify, resolve, and prevent any DRPs
To ensure that the patient’s therapeutic goals are met and that
optimal health-related outcomes are attained.
8Anas Bahnassi PhD CDM CDE
Drug Related Problems
DRPs
– To resolve identified DTPs and to prevent future
problems, pharmacist must understand the causes of
these problems.
– The pharmacist must use a consistent, systematic and
comprehensive process Pharmaceutical Care
process
DRP is any undesirable event experienced by the
patient that involves drug therapy and that actually
(or potentially) interferes with a desired patient
outcome.
9Anas Bahnassi PhD CDM CDE
Common DRPs
and Their causes
DRP Type Possible Causes
Unnecessary Drug
Prescribed
No Indication
Duplicate Therapy
Wrong Drug Contraindications present
Drug not indicated for conditions
More effective medic. available
Drug interaction
Indication refractory to drug
Inappropriate dosage form
Dose Too Low Wrong dose
Inappropriate frequency
Inappropriate duration
Incorrect storage
Incorrect administration
Drug interaction 10Anas Bahnassi PhD CDM CDE
Common DRPs
and Their causes
DRP Type Possible Causes
Dose Too High Wrong dose
Inappropriate frequency
Inappropriate duration
Incorrect administration
Drug interaction
Adverse Drug Reactions Undesirable drug side effect
Allergic reaction
Drug interaction
Incorrect administration
Dose changed too quickly
Unsafe drug for the patient
11Anas Bahnassi PhD CDM CDE
Common DRPs
and Their causes
DRP Type Possible Causes
Noncompliance Cannot afford drug
Doesn’t understand instructions on how to take
the drug
Cannot swallow/administer the drug
Drug not available
Additional drug therapy Untreated condition
Prophylactic therapy
Synergistic therapy
12Anas Bahnassi PhD CDM CDE
Pharmaceutical Care
Process
• Initiating a relationship with the patient
– patient bringing a new prescription to the pharmacy
or asking about a nonprescription drug
• Pharmacist gathers all the pertinent information
to evaluate the patient’s health and drug therapy
appropriately
– subjective information (patient complaints and
symptoms)
– objective information (medication profile, vital signs,
or physical assessment data)
13Anas Bahnassi PhD CDM CDE
Pharmaceutical Care
Process
• Pharmacist assess the information and looks for
DRPs.
• The DTPs are prioritized along with corresponding
goals and goal criteria, and documented in
pharmaceutical care plan (PCP)
• Integral to the PCP, pharmacist develop the
solutions to DRPs (= interventions).
• Develop the monitoring plan, which outlines
factors that will determine attainment of the
desired patient outcomes (BP measurement, lab
data, talking with patient).
14Anas Bahnassi PhD CDM CDE
Pharmaceutical Care
Process
• Implement follow-up, which includes
implementing the monitoring plan (ex. Contact
the patient to evaluate drug therapy compliance
or drug side effects). Other follow up may
include measuring vital signs or checking other
physical or lab data.
NOTE:
• Ideally, the patient should be involved throughout the entire
pharmaceutical care process.
• After that plan has been implemented, the PCP recycles once again. The
pharmacist gather more data, assess the Px progress, and adjust the
plan.
15Anas Bahnassi PhD CDM CDE
For successfully incorporate
Pharmaceutical Care into
Practice, the Pharmacist
must have knowledge and
skills in Patient
Assessment
16Anas Bahnassi PhD CDM CDE
Patient Assessment
Patient assessment is the process
through which the pharmacist evaluate
the patient information (both objective
and subjective) that was gathered from
the patient and other sources (e.g. drug
therapy profile, medical record, etc.)
17Anas Bahnassi PhD CDM CDE
Patient Assessment
Means:
Making
decisions
regarding:
1. The health status of the
patient.
2. Drug therapy needs and
problems.
3. Interventions that will
resolve identified drug
problems and future
problems
4. Follow-up to ensure that
patient outcomes are
being met.
18Anas Bahnassi PhD CDM CDE
Purpose of
Patient Assessment:
A pharmacist cannot
adequately provide
pharmaceutical care
without assessing
patients.
• To identify,
• To resolve, and
• To prevent drug
related problems.
19Anas Bahnassi PhD CDM CDE
Patient Assessment
Should be done by:
• Asking a series of questions:
• These questions will guide the pharmacist
through the assessment process.
• Assess the patient’s physical
conditions:
• e g. skin abnormalities, obtainment of
vital signs, peak flow readings, blood
glucose levels, cholesterol values.
20Anas Bahnassi PhD CDM CDE
Documentation:
• Provides a permanent record of patient
information.
• Provides a permanent record and evidence of
pharmaceutical care activities by the pharmacist.
• Communicates essential
information to other pharmacists
and health care professionals.
• Serves as a legal record of patient
care that was provided.
• Provides back-up for billing
purposes.
21Anas Bahnassi PhD CDM CDE
Characteristics of
Useful Patient Records:
• Information that is neat, organized, and able to be found
quickly.
• Information that is easily understandable, so that any health
care professional can determine what the problems were,
what actions were taken, and what follow-up is needed.
• Accurate subjective and objective information.
• An assessment of the patient
information, focusing on DRPs.
• A plan to resolve any problems that
were identified.
• A plan for future follow-up to ensure that any problems are
resolved and that patient outcomes are met.
22Anas Bahnassi PhD CDM CDE
SOAP Note
23Anas Bahnassi PhD CDM CDE
SOAP Note:
Subjective:
Includes information that
is given by the patient,
family members,
significant others, or
care givers.
• Complaint/symptoms in his/her
own words
• Recent history that pertains ti
those symptoms (history of
present illness)
• Past medical history
• Medication history, including
compliance & ADRs.
• Allergies
• Social and/or family history
• Review of systems.
This type of
information contains:
24Anas Bahnassi PhD CDM CDE
SOAP Note:
Objective:
Includes data that are
obtained from the
patient and that can
be measured objectively.
• Vital signs.
• Physical findings or physical
examination (if possible).
• Laboratory test results (if
available).
• Serum drug concentrations (if
available).
• Various diagnostic test results (if
available).
• Computerized medication profile
with refill information (if
available).
This type of
information contains:
25Anas Bahnassi PhD CDM CDE
SOAP Note:
Assessment:
• Analyzes subjective and objective
information.
• Determines the health status of
the patient.
• Is the patient experiencing a
DRP?
• Have the patient’s outcomes
been met?
• Provides the basis and rationale
for the plan.
The
pharmacist:
26Anas Bahnassi PhD CDM CDE
SOAP Note:
Plan:
• Actions that were—or need to be—
taken to resolve any problems that
have been identified.
• Follow-up to ensure that problems
are actually corrected and that
future problems do not develop.
• The follow-up should include
monitoring parameters that
need to be assessed as well as
the interval for the next
assessments
It involves:
27Anas Bahnassi PhD CDM CDE
SOAP Note:
Plan:
• Guidelines should be done with
the data at the time of the
follow-up.
• Simplicity and reproducibility:
• A colleague should be able to
read, interpret, and act on
the plan if the pharmacist
who documented the note is
not available.
It involves:
28Anas Bahnassi PhD CDM CDE
Pharmaceutical
Care Plan:
Name: M.H
Gender: F
Date: 9/2/2014
Complaint: HTN.
Drugs Used:
Atenolol 25mg QD.
Captopril 12.5mg
BID
• The patient is picking up her
Atenolol Rx.
• She feels:
• Head lightness.
• Weakness.
• Impaired balance for 2 weeks.
• She has been taking Atenolol BID
instead of QD this week.
Subjective:
29Anas Bahnassi PhD CDM CDE
Pharmaceutical
Care Plan:
Name: M.H
Gender: F
Date: 9/2/2014
Complaint: HTN.
Drugs Used:
Atenolol 25mg QD.
Captopril 12.5mg
BID
• The patient was staggering at the
pharmacy counter.
• Pulse is: 48 bpm.
• Blood pressure is:
114/72 mm Hg
112/70 mm Hg
Objective:
30Anas Bahnassi PhD CDM CDE
Pharmaceutical
Care Plan:
Name: M.H
Gender: F
Date: 9/2/2014
Complaint: HTN.
Drugs Used:
Atenolol 25mg QD.
Captopril 12.5mg
BID
• Bradycardia and hypotension-
new-onset may be due
noncompliance with atenolol
dosing.
Assessment:
31Anas Bahnassi PhD CDM CDE
Pharmaceutical
Care Plan:
Name: M.H
Gender: F
Date: 9/2/2014
Complaint: HTN.
Drugs Used:
Atenolol 25mg QD.
Captopril 12.5mg
BID
• Inform the patient to take
atenolol once a day with
breakfast and captopril 2 times
daily as usual.
• For the follow-up a week later
recheck pulse and blood
pressure.
• If still low, ask her to contact
her doctor and suggest
lowering the dose atenolol.
Plan:
32Anas Bahnassi PhD CDM CDE
Clinical Pharmacy VI:
First Aid
Anas Bahnassi PhD CDM CDE
abahnassi@gmail.com
http://www.twitter.com/abpharm
http://www.facebook.com/pharmaprof
http://www.linkedin.com/in/abahnassi

Weitere ähnliche Inhalte

Was ist angesagt?

Rational prescribing,dispensing and use of drugs
Rational prescribing,dispensing and use of drugsRational prescribing,dispensing and use of drugs
Rational prescribing,dispensing and use of drugsAhmad Ali
 
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Anjali Rarichan
 
14ab1t0017 procurement and warehousing of radiopharmaceuticals
14ab1t0017   procurement and warehousing of radiopharmaceuticals14ab1t0017   procurement and warehousing of radiopharmaceuticals
14ab1t0017 procurement and warehousing of radiopharmaceuticalsRamesh Ganpisetti
 
WAREHOUSING OF DRUGS
WAREHOUSING OF DRUGSWAREHOUSING OF DRUGS
WAREHOUSING OF DRUGSaishuanju
 
Pharmaceutical care plan
Pharmaceutical care planPharmaceutical care plan
Pharmaceutical care planNorliza Ariffin
 
14ab1t0012 dispensing of narcotics and controlled substances
14ab1t0012   dispensing of narcotics and controlled substances14ab1t0012   dispensing of narcotics and controlled substances
14ab1t0012 dispensing of narcotics and controlled substancesRamesh Ganpisetti
 
Patient compliance
Patient compliancePatient compliance
Patient complianceKiran Sharma
 
clinical pharmacy
clinical pharmacyclinical pharmacy
clinical pharmacySohan Patel
 
Drug distribution system in Hospital
Drug distribution system in HospitalDrug distribution system in Hospital
Drug distribution system in HospitalSubhash Yende
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingTHUSHARA MOHAN
 
Prescription and Drug prescription Writing
Prescription and Drug prescription WritingPrescription and Drug prescription Writing
Prescription and Drug prescription WritingEneutron
 
Role of the pharmacist in medication safety.
Role of the pharmacist in medication safety.Role of the pharmacist in medication safety.
Role of the pharmacist in medication safety.Subash321
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacyKARTHIKA K.J
 
Adverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & ReportingAdverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & ReportingRuella D'Costa Fernandes
 
Introduction to dispensing and medication counseling
Introduction to dispensing and medication counselingIntroduction to dispensing and medication counseling
Introduction to dispensing and medication counselingIvory Diane Amancio
 

Was ist angesagt? (20)

Rational prescribing,dispensing and use of drugs
Rational prescribing,dispensing and use of drugsRational prescribing,dispensing and use of drugs
Rational prescribing,dispensing and use of drugs
 
Drug Therapy Monitoring
Drug Therapy MonitoringDrug Therapy Monitoring
Drug Therapy Monitoring
 
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
 
14ab1t0017 procurement and warehousing of radiopharmaceuticals
14ab1t0017   procurement and warehousing of radiopharmaceuticals14ab1t0017   procurement and warehousing of radiopharmaceuticals
14ab1t0017 procurement and warehousing of radiopharmaceuticals
 
WAREHOUSING OF DRUGS
WAREHOUSING OF DRUGSWAREHOUSING OF DRUGS
WAREHOUSING OF DRUGS
 
Pharmaceutical care plan
Pharmaceutical care planPharmaceutical care plan
Pharmaceutical care plan
 
14ab1t0012 dispensing of narcotics and controlled substances
14ab1t0012   dispensing of narcotics and controlled substances14ab1t0012   dispensing of narcotics and controlled substances
14ab1t0012 dispensing of narcotics and controlled substances
 
Patient compliance
Patient compliancePatient compliance
Patient compliance
 
clinical pharmacy
clinical pharmacyclinical pharmacy
clinical pharmacy
 
Drug distribution system in Hospital
Drug distribution system in HospitalDrug distribution system in Hospital
Drug distribution system in Hospital
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
 
Prescription and Drug prescription Writing
Prescription and Drug prescription WritingPrescription and Drug prescription Writing
Prescription and Drug prescription Writing
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
 
hospital formulary
hospital formularyhospital formulary
hospital formulary
 
Role of the pharmacist in medication safety.
Role of the pharmacist in medication safety.Role of the pharmacist in medication safety.
Role of the pharmacist in medication safety.
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacy
 
Adverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & ReportingAdverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & Reporting
 
Introduction to dispensing and medication counseling
Introduction to dispensing and medication counselingIntroduction to dispensing and medication counseling
Introduction to dispensing and medication counseling
 
Introduction to hospital pharmacy
Introduction to hospital pharmacyIntroduction to hospital pharmacy
Introduction to hospital pharmacy
 
Patient counselling
Patient counsellingPatient counselling
Patient counselling
 

Ähnlich wie Lecture one: Patient Assessment in Pharmacy Practice

1 The pharmacist’s Role in Self Care.pptx
1 The pharmacist’s Role in Self Care.pptx1 The pharmacist’s Role in Self Care.pptx
1 The pharmacist’s Role in Self Care.pptxDrAllaAddinAlsyany
 
PCN 612 PATIENT DATA EVALUATION.pptx
PCN 612 PATIENT DATA EVALUATION.pptxPCN 612 PATIENT DATA EVALUATION.pptx
PCN 612 PATIENT DATA EVALUATION.pptxStevenABaqrEgili
 
PHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docxPHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docxNbkKarim1
 
Workshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseWorkshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseaaltunalboro
 
Mitigating Risk When Managing High Dose, Chronic Pain Patients
Mitigating Risk When Managing High Dose, Chronic Pain Patients Mitigating Risk When Managing High Dose, Chronic Pain Patients
Mitigating Risk When Managing High Dose, Chronic Pain Patients Polsinelli PC
 
Pharmacy practice.pdf
Pharmacy practice.pdfPharmacy practice.pdf
Pharmacy practice.pdfUVAS
 
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...BU School of Medicine
 
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshRx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshOPUNITE
 
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreinerRx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreinerOPUNITE
 
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01pmppowerpoint
 
RDP-CP-PP.pdf
RDP-CP-PP.pdfRDP-CP-PP.pdf
RDP-CP-PP.pdfrishi2789
 
Patient adherence – what’s the problem?
Patient adherence – what’s the problem?Patient adherence – what’s the problem?
Patient adherence – what’s the problem?PM Society
 
Rx15 pdmp wed_300_1_stripp_2lev-lucas
Rx15 pdmp wed_300_1_stripp_2lev-lucasRx15 pdmp wed_300_1_stripp_2lev-lucas
Rx15 pdmp wed_300_1_stripp_2lev-lucasOPUNITE
 
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01pmppowerpoint
 
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01pmppowerpoint
 
Intentional re-challenge and the clinical data management of Drug Related pro...
Intentional re-challenge and the clinical data management of Drug Related pro...Intentional re-challenge and the clinical data management of Drug Related pro...
Intentional re-challenge and the clinical data management of Drug Related pro...ClinosolIndia
 
Clinical pharmacy ppt
Clinical pharmacy pptClinical pharmacy ppt
Clinical pharmacy pptNabi Hasan
 
Point of Care
Point of CarePoint of Care
Point of Caregrowell
 

Ähnlich wie Lecture one: Patient Assessment in Pharmacy Practice (20)

1 The pharmacist’s Role in Self Care.pptx
1 The pharmacist’s Role in Self Care.pptx1 The pharmacist’s Role in Self Care.pptx
1 The pharmacist’s Role in Self Care.pptx
 
PCN 612 PATIENT DATA EVALUATION.pptx
PCN 612 PATIENT DATA EVALUATION.pptxPCN 612 PATIENT DATA EVALUATION.pptx
PCN 612 PATIENT DATA EVALUATION.pptx
 
PHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docxPHARMACEUTICAL CARE.docx
PHARMACEUTICAL CARE.docx
 
Workshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseWorkshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcase
 
Mitigating Risk When Managing High Dose, Chronic Pain Patients
Mitigating Risk When Managing High Dose, Chronic Pain Patients Mitigating Risk When Managing High Dose, Chronic Pain Patients
Mitigating Risk When Managing High Dose, Chronic Pain Patients
 
Pharmacy practice.pdf
Pharmacy practice.pdfPharmacy practice.pdf
Pharmacy practice.pdf
 
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
Building an Collaborative Care Infrastructure for Opioid-Addicted Patients in...
 
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshRx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
 
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreinerRx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
Rx15 pdmp tues_200_1_hildebran-leichtling_2kreiner
 
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
Rx15pdmptues2001hildebran leichtling2kreiner-150402160254-conversion-gate01
 
RDP-CP-PP.pdf
RDP-CP-PP.pdfRDP-CP-PP.pdf
RDP-CP-PP.pdf
 
Patient adherence – what’s the problem?
Patient adherence – what’s the problem?Patient adherence – what’s the problem?
Patient adherence – what’s the problem?
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
 
Rx15 pdmp wed_300_1_stripp_2lev-lucas
Rx15 pdmp wed_300_1_stripp_2lev-lucasRx15 pdmp wed_300_1_stripp_2lev-lucas
Rx15 pdmp wed_300_1_stripp_2lev-lucas
 
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
 
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
Rx15pdmpwed3001stripp2lev lucas-150402160641-conversion-gate01
 
Intentional re-challenge and the clinical data management of Drug Related pro...
Intentional re-challenge and the clinical data management of Drug Related pro...Intentional re-challenge and the clinical data management of Drug Related pro...
Intentional re-challenge and the clinical data management of Drug Related pro...
 
Clinical pharmacy ppt
Clinical pharmacy pptClinical pharmacy ppt
Clinical pharmacy ppt
 
Point of Care
Point of CarePoint of Care
Point of Care
 
Pharmaceutical care
Pharmaceutical carePharmaceutical care
Pharmaceutical care
 

Mehr von Anas Bahnassi أنس البهنسي

Pharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part OnePharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part OneAnas Bahnassi أنس البهنسي
 

Mehr von Anas Bahnassi أنس البهنسي (20)

Lecture nine cardiovascular_emeregencies
Lecture nine cardiovascular_emeregenciesLecture nine cardiovascular_emeregencies
Lecture nine cardiovascular_emeregencies
 
Urinary Tract Infections
Urinary Tract InfectionsUrinary Tract Infections
Urinary Tract Infections
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Influenza
InfluenzaInfluenza
Influenza
 
Acute bronchitis
Acute bronchitisAcute bronchitis
Acute bronchitis
 
Sinusitis
SinusitisSinusitis
Sinusitis
 
Streptococccal sore throat
Streptococccal sore throatStreptococccal sore throat
Streptococccal sore throat
 
Acute Otitis Media
Acute Otitis Media Acute Otitis Media
Acute Otitis Media
 
Principles of infectious diseases
Principles of infectious diseasesPrinciples of infectious diseases
Principles of infectious diseases
 
Lecture three management cycle Part 3
Lecture three management cycle Part 3Lecture three management cycle Part 3
Lecture three management cycle Part 3
 
Lecture two management cycle Part: 2
Lecture two management cycle Part: 2Lecture two management cycle Part: 2
Lecture two management cycle Part: 2
 
Pharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part OnePharmacy Practice: Lecture one: Medication Management Cycle Part One
Pharmacy Practice: Lecture one: Medication Management Cycle Part One
 
Osteoarthritis
OsteoarthritisOsteoarthritis
Osteoarthritis
 
Juvenile idiopathic arthritis
Juvenile idiopathic arthritisJuvenile idiopathic arthritis
Juvenile idiopathic arthritis
 
Rheumatoid arthritis Part 2
Rheumatoid arthritis Part 2Rheumatoid arthritis Part 2
Rheumatoid arthritis Part 2
 
Rheumatoid Arthritis Part !
Rheumatoid Arthritis Part !Rheumatoid Arthritis Part !
Rheumatoid Arthritis Part !
 
Pharmacotherapy of Diabetes: Part 2
Pharmacotherapy of Diabetes: Part 2Pharmacotherapy of Diabetes: Part 2
Pharmacotherapy of Diabetes: Part 2
 
Role of community pharmacists in diabetes management
Role of community pharmacists in diabetes managementRole of community pharmacists in diabetes management
Role of community pharmacists in diabetes management
 
Diabetes Care: Part One
Diabetes Care: Part OneDiabetes Care: Part One
Diabetes Care: Part One
 
Premixed insulin dosing in actual practice
Premixed insulin dosing in actual practicePremixed insulin dosing in actual practice
Premixed insulin dosing in actual practice
 

Kürzlich hochgeladen

Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and ModificationsMJDuyan
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.pptRamjanShidvankar
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...christianmathematics
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - Englishneillewis46
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptxMaritesTamaniVerdade
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsKarakKing
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the ClassroomPooky Knightsmith
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxcallscotland1987
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxAmanpreet Kaur
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfSherif Taha
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxDr. Sarita Anand
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxEsquimalt MFRC
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Association for Project Management
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701bronxfugly43
 

Kürzlich hochgeladen (20)

Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptx
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701
 

Lecture one: Patient Assessment in Pharmacy Practice

  • 1. Patient Care in Pharmacy Practice Anas Bahnassi PhD
  • 2. Anas Bahnassi PhD CDM CDE 2
  • 3. Patient-Centered Care Care centered on patients’ needs and expectations 3Anas Bahnassi PhD CDM CDE
  • 4. Goals of Pharmaceutical Care Cure of a disease Elimination or reduction of a patient’s symptoms Arresting or slowing of a disease process Preventing a disease or symptomatology 4Anas Bahnassi PhD CDM CDE
  • 5. The central component of Pharmaceutical Care is: CARING ABOUT THE PATIENT. 5Anas Bahnassi PhD CDM CDE
  • 6. Pharmaceutical Care Process Initiate relationship with the patient or caregiver Gather patient information (subjective and objective) Assess info (patient assessment) Develop pharmaceutical care plan Complete InterventionImplement follow-up 6Anas Bahnassi PhD CDM CDE
  • 7. Primary Elements of Pharmaceutical Care The need of the society to address Drug Related Problems (DRPs) A patient-centered approach to meet this need A practice based on “caring” about and for patients Responsibility for finding and responding to the patient’s DRPs 7Anas Bahnassi PhD CDM CDE
  • 8. Pharmacist responsibility in Pharmaceutical Care To ensure that the patient’s drug therapy is appropriately indicated, the most effective available, the safest possible, the most convenient to take, and the most economical To identify, resolve, and prevent any DRPs To ensure that the patient’s therapeutic goals are met and that optimal health-related outcomes are attained. 8Anas Bahnassi PhD CDM CDE
  • 9. Drug Related Problems DRPs – To resolve identified DTPs and to prevent future problems, pharmacist must understand the causes of these problems. – The pharmacist must use a consistent, systematic and comprehensive process Pharmaceutical Care process DRP is any undesirable event experienced by the patient that involves drug therapy and that actually (or potentially) interferes with a desired patient outcome. 9Anas Bahnassi PhD CDM CDE
  • 10. Common DRPs and Their causes DRP Type Possible Causes Unnecessary Drug Prescribed No Indication Duplicate Therapy Wrong Drug Contraindications present Drug not indicated for conditions More effective medic. available Drug interaction Indication refractory to drug Inappropriate dosage form Dose Too Low Wrong dose Inappropriate frequency Inappropriate duration Incorrect storage Incorrect administration Drug interaction 10Anas Bahnassi PhD CDM CDE
  • 11. Common DRPs and Their causes DRP Type Possible Causes Dose Too High Wrong dose Inappropriate frequency Inappropriate duration Incorrect administration Drug interaction Adverse Drug Reactions Undesirable drug side effect Allergic reaction Drug interaction Incorrect administration Dose changed too quickly Unsafe drug for the patient 11Anas Bahnassi PhD CDM CDE
  • 12. Common DRPs and Their causes DRP Type Possible Causes Noncompliance Cannot afford drug Doesn’t understand instructions on how to take the drug Cannot swallow/administer the drug Drug not available Additional drug therapy Untreated condition Prophylactic therapy Synergistic therapy 12Anas Bahnassi PhD CDM CDE
  • 13. Pharmaceutical Care Process • Initiating a relationship with the patient – patient bringing a new prescription to the pharmacy or asking about a nonprescription drug • Pharmacist gathers all the pertinent information to evaluate the patient’s health and drug therapy appropriately – subjective information (patient complaints and symptoms) – objective information (medication profile, vital signs, or physical assessment data) 13Anas Bahnassi PhD CDM CDE
  • 14. Pharmaceutical Care Process • Pharmacist assess the information and looks for DRPs. • The DTPs are prioritized along with corresponding goals and goal criteria, and documented in pharmaceutical care plan (PCP) • Integral to the PCP, pharmacist develop the solutions to DRPs (= interventions). • Develop the monitoring plan, which outlines factors that will determine attainment of the desired patient outcomes (BP measurement, lab data, talking with patient). 14Anas Bahnassi PhD CDM CDE
  • 15. Pharmaceutical Care Process • Implement follow-up, which includes implementing the monitoring plan (ex. Contact the patient to evaluate drug therapy compliance or drug side effects). Other follow up may include measuring vital signs or checking other physical or lab data. NOTE: • Ideally, the patient should be involved throughout the entire pharmaceutical care process. • After that plan has been implemented, the PCP recycles once again. The pharmacist gather more data, assess the Px progress, and adjust the plan. 15Anas Bahnassi PhD CDM CDE
  • 16. For successfully incorporate Pharmaceutical Care into Practice, the Pharmacist must have knowledge and skills in Patient Assessment 16Anas Bahnassi PhD CDM CDE
  • 17. Patient Assessment Patient assessment is the process through which the pharmacist evaluate the patient information (both objective and subjective) that was gathered from the patient and other sources (e.g. drug therapy profile, medical record, etc.) 17Anas Bahnassi PhD CDM CDE
  • 18. Patient Assessment Means: Making decisions regarding: 1. The health status of the patient. 2. Drug therapy needs and problems. 3. Interventions that will resolve identified drug problems and future problems 4. Follow-up to ensure that patient outcomes are being met. 18Anas Bahnassi PhD CDM CDE
  • 19. Purpose of Patient Assessment: A pharmacist cannot adequately provide pharmaceutical care without assessing patients. • To identify, • To resolve, and • To prevent drug related problems. 19Anas Bahnassi PhD CDM CDE
  • 20. Patient Assessment Should be done by: • Asking a series of questions: • These questions will guide the pharmacist through the assessment process. • Assess the patient’s physical conditions: • e g. skin abnormalities, obtainment of vital signs, peak flow readings, blood glucose levels, cholesterol values. 20Anas Bahnassi PhD CDM CDE
  • 21. Documentation: • Provides a permanent record of patient information. • Provides a permanent record and evidence of pharmaceutical care activities by the pharmacist. • Communicates essential information to other pharmacists and health care professionals. • Serves as a legal record of patient care that was provided. • Provides back-up for billing purposes. 21Anas Bahnassi PhD CDM CDE
  • 22. Characteristics of Useful Patient Records: • Information that is neat, organized, and able to be found quickly. • Information that is easily understandable, so that any health care professional can determine what the problems were, what actions were taken, and what follow-up is needed. • Accurate subjective and objective information. • An assessment of the patient information, focusing on DRPs. • A plan to resolve any problems that were identified. • A plan for future follow-up to ensure that any problems are resolved and that patient outcomes are met. 22Anas Bahnassi PhD CDM CDE
  • 24. SOAP Note: Subjective: Includes information that is given by the patient, family members, significant others, or care givers. • Complaint/symptoms in his/her own words • Recent history that pertains ti those symptoms (history of present illness) • Past medical history • Medication history, including compliance & ADRs. • Allergies • Social and/or family history • Review of systems. This type of information contains: 24Anas Bahnassi PhD CDM CDE
  • 25. SOAP Note: Objective: Includes data that are obtained from the patient and that can be measured objectively. • Vital signs. • Physical findings or physical examination (if possible). • Laboratory test results (if available). • Serum drug concentrations (if available). • Various diagnostic test results (if available). • Computerized medication profile with refill information (if available). This type of information contains: 25Anas Bahnassi PhD CDM CDE
  • 26. SOAP Note: Assessment: • Analyzes subjective and objective information. • Determines the health status of the patient. • Is the patient experiencing a DRP? • Have the patient’s outcomes been met? • Provides the basis and rationale for the plan. The pharmacist: 26Anas Bahnassi PhD CDM CDE
  • 27. SOAP Note: Plan: • Actions that were—or need to be— taken to resolve any problems that have been identified. • Follow-up to ensure that problems are actually corrected and that future problems do not develop. • The follow-up should include monitoring parameters that need to be assessed as well as the interval for the next assessments It involves: 27Anas Bahnassi PhD CDM CDE
  • 28. SOAP Note: Plan: • Guidelines should be done with the data at the time of the follow-up. • Simplicity and reproducibility: • A colleague should be able to read, interpret, and act on the plan if the pharmacist who documented the note is not available. It involves: 28Anas Bahnassi PhD CDM CDE
  • 29. Pharmaceutical Care Plan: Name: M.H Gender: F Date: 9/2/2014 Complaint: HTN. Drugs Used: Atenolol 25mg QD. Captopril 12.5mg BID • The patient is picking up her Atenolol Rx. • She feels: • Head lightness. • Weakness. • Impaired balance for 2 weeks. • She has been taking Atenolol BID instead of QD this week. Subjective: 29Anas Bahnassi PhD CDM CDE
  • 30. Pharmaceutical Care Plan: Name: M.H Gender: F Date: 9/2/2014 Complaint: HTN. Drugs Used: Atenolol 25mg QD. Captopril 12.5mg BID • The patient was staggering at the pharmacy counter. • Pulse is: 48 bpm. • Blood pressure is: 114/72 mm Hg 112/70 mm Hg Objective: 30Anas Bahnassi PhD CDM CDE
  • 31. Pharmaceutical Care Plan: Name: M.H Gender: F Date: 9/2/2014 Complaint: HTN. Drugs Used: Atenolol 25mg QD. Captopril 12.5mg BID • Bradycardia and hypotension- new-onset may be due noncompliance with atenolol dosing. Assessment: 31Anas Bahnassi PhD CDM CDE
  • 32. Pharmaceutical Care Plan: Name: M.H Gender: F Date: 9/2/2014 Complaint: HTN. Drugs Used: Atenolol 25mg QD. Captopril 12.5mg BID • Inform the patient to take atenolol once a day with breakfast and captopril 2 times daily as usual. • For the follow-up a week later recheck pulse and blood pressure. • If still low, ask her to contact her doctor and suggest lowering the dose atenolol. Plan: 32Anas Bahnassi PhD CDM CDE
  • 33. Clinical Pharmacy VI: First Aid Anas Bahnassi PhD CDM CDE abahnassi@gmail.com http://www.twitter.com/abpharm http://www.facebook.com/pharmaprof http://www.linkedin.com/in/abahnassi